Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11216208 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 | |
| SCHEMBL1178106 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL1291958 | 0.76 | ALPG (0.49) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 | |
| SCHEMBL3762300 | 0.74 | — | — | |
| Water SCHEMBL11813782 | 0.74 | HMOX1 (0.51) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 | |
| SCHEMBL48809 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL1375622 | 0.74 | HMOX1 (0.51) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 | |
| SCHEMBL2825206 | 0.73 | FOLH1 (0.38) | ALDH1A1PKM | |
| SCHEMBL315947 | 0.73 | ALDH1A1 (0.52) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 | |
| Lithium Ion SCHEMBL11855287 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HSD17B10MEN1KMT2AHMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185575-B1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-116234801-A | Heteroaryl-methyl substituted triazoles as vasopressin receptor V1A antagonists | 豪夫迈·罗氏有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4185575-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-02-18 | — | — | US | disclosed |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-12-27 | — | — | US | disclosed |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | ALDH1A1 1768/4885HSD17B10 3709/4885MEN1 2845/4885 |
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | CYP3A43, CYP3A4, CYP4B1 | ALDH1A1 943/4885HSD17B10 1579/4885MEN1 381/4885 |
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | ALDH1A1 1768/4885HSD17B10 3709/4885MEN1 2845/4885 |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | ALDH1A1 1768/4885HSD17B10 3709/4885MEN1 2845/4885 |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | ALDH1A1 1768/4885HSD17B10 3709/4885MEN1 2845/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | ALDH1A1 2650/4885HSD17B10 293/4885MEN1 2639/4885 |
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | TST, THPO, STS | ALDH1A1 2258/4885HSD17B10 1728/4885MEN1 2415/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | ALDH1A1 2031/4885HSD17B10 2776/4885MEN1 1081/4885 |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | ALDH1A1 1768/4885HSD17B10 3709/4885MEN1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.